In vivo assessment of NuvaRing placement
- PMID: 16102555
- DOI: 10.1016/j.contraception.2005.03.012
In vivo assessment of NuvaRing placement
Abstract
NuvaRing, a combined contraceptive vaginal ring 54 mm in diameter, offers many advantages over oral contraceptives. To better delineate in vivo placement, we performed MRI to confirm its anatomical position. Two healthy users, one nulliparous and one parous, underwent a series of MRI: preinsertion, immediately postinsertion and after ambulation. Three-dimensional imaging of the human vagina demonstrates that in vivo, NuvaRing is located superior to the urogenital diaphragm (UGD), surrounding the cervix. The superior-most aspect of the ring lies behind (posterior) the cervix, at a level superior to the external os. The inferior aspect of the ring also lies in the vaginal canal above the UGD. The entire cervix rests inside the ring. The preambulation image in the nulliparous woman was the only exception. In this case, the upper portion of the ring was at the level of the lower-mid cervix and the lower aspect below the UGD. After ambulation, the ring moved cephalad and surrounded the cervix. In all instances, ambulation resulted in lower aspect of NuvaRing moving away from the introitus. In vivo, NuvaRing is compressed laterally forming a gentle oval in the anterior-posterior direction (5-7 mm longer than wide), an effect that is seen more in nulliparous women.
Similar articles
-
Magnetic resonance imaging of SILCS diaphragm: anatomical considerations and corroboration with clinical fit.Contraception. 2007 Sep;76(3):238-44. doi: 10.1016/j.contraception.2007.05.090. Epub 2007 Jul 23. Contraception. 2007. PMID: 17707723
-
Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany.Eur J Contracept Reprod Health Care. 2008 Mar;13(1):31-8. doi: 10.1080/13625180701577122. Eur J Contracept Reprod Health Care. 2008. PMID: 17853162
-
The combined contraceptive vaginal device (NuvaRing): a comprehensive review.Eur J Contracept Reprod Health Care. 2005 Jun;10(2):73-8. doi: 10.1080/13625180500131683. Eur J Contracept Reprod Health Care. 2005. PMID: 16147810 Review.
-
The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands.Eur J Contracept Reprod Health Care. 2006 Mar;11(1):14-22. doi: 10.1080/13625180500389547. Eur J Contracept Reprod Health Care. 2006. PMID: 16546812
-
High acceptability and satisfaction with NuvaRing use.Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:31-6; discussion 37-9. Eur J Contracept Reprod Health Care. 2002. PMID: 12659400 Review.
Cited by
-
Advances in contraception: vaginal contraceptive rings.Ther Adv Reprod Health. 2023 Jul 14;17:26334941231186733. doi: 10.1177/26334941231186733. eCollection 2023 Jan-Dec. Ther Adv Reprod Health. 2023. PMID: 37465002 Free PMC article. Review.
-
Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).Int J Womens Health. 2010 Nov 12;2:401-9. doi: 10.2147/IJWH.S6162. Int J Womens Health. 2010. PMID: 21151688 Free PMC article.
-
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.Antimicrob Agents Chemother. 2012 Dec;56(12):6272-83. doi: 10.1128/AAC.01431-12. Epub 2012 Sep 24. Antimicrob Agents Chemother. 2012. PMID: 23006751 Free PMC article.
-
Engineering a degradable polyurethane intravaginal ring for sustained delivery of dapivirine.Drug Deliv Transl Res. 2011 Jun;1(3):223-37. doi: 10.1007/s13346-011-0027-1. Drug Deliv Transl Res. 2011. PMID: 25788241
-
Compartmental transport model of microbicide delivery by an intravaginal ring.J Pharm Sci. 2010 Aug;99(8):3514-21. doi: 10.1002/jps.22120. J Pharm Sci. 2010. PMID: 20222027 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical